

# *The microbiome in health and disease*




***A/Prof Geraint Rogers***  
***SAHMRI Microbiome Research***



**Microbiome  
Research**




# Rise of the microbiome



**Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity**

BY ALEXANDRA ZHERNAKOVA, ALEXANDER KURILSHIKOV, ET AL. | APR. 29, 2016



**Durable coexistence of donor and recipient strains after fecal microbiota transplantation**

BY SIMONE S. LI, ANA ZHU, ET AL. | APR. 29, 2016



**Gut microbes linked to eye disease**

BY MITCH LESLIE | AUG. 18, 2015



**Special issue: Microbiota at work**

BY CAROLINE ASH, KRISTEN MUELLER | APR. 29, 2016



**The right gut microbes help infants grow**

BY ELIZABETH PENNISI | FEB. 18, 2016



**How to give a C-section baby the potential benefits of vaginal birth**

BY JENNIFER COUZIN-FRANKEL | FEB. 1, 2016



**Your poor diet might hurt your grandchildren's guts**

BY KATHERINE HARMON COURAGE | JAN. 13, 2016




**Gut microbes give anticancer treatments a boost**

BY MITCH LESLIE | NOV. 5, 2015



**You're surrounded by your own personal cloud of microbes**

BY HANAE ARMITAGE | SEP. 22, 2015




**Cross-species comparisons of host genetic associations with the microbiome**

BY JULIA K. GOODRICH, EMILY R. DAVENPORT, ET AL. | APR. 29, 2016




**Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens**

BY ERIC G. PAMER | APR. 29, 2016




**How colonization by microbiota in early life shapes the immune system**

BY THOMAS GENSOLLEN, SHANKAR S. IYER, ET AL. | APR. 29, 2016



**Antibiotic use and its consequences for the normal microbiome**


BY MARTIN J. BLASER | APR. 29, 2016




**Population-level analysis of gut microbiome variation**

BY GWEN FALONY, MARIE JOOSSENS, ET AL. | APR. 29, 2016


# Culture-independent microbiology



DNA



## Sequence-based microbiology



# The sequencing revolution



## Human Genome Project

Completed 2003


Cost: \$2,700,000,000

January, 2014


Human genome sequence <\$1000

Less than the cost of a chest X-ray

## Sequencing costs



## Publications featuring "microbiome"




# The human superorganism

**MICROBIAL CELLS**  
-100 TRILLION  
(-70-90%)



**HUMAN CELLS**  
-30 TRILLION

**MICROBIAL GENES**  
-2,000,000  
(-99%)




**HUMAN GENES**  
-23,000




# What has the microbiome ever done for us?




CNS function



Immune regulation



Lipid and glucose metabolism



Prevention of infection




Nutrition

## Circadian rhythm

### Transkingdom Control of Microbiota Diurnal Oscillations Promotes Metabolic Homeostasis

Christoph A. Thaiss,<sup>1</sup> David Zeevi,<sup>2</sup> Maayan Levy,<sup>1</sup> Gili Zilberman-Schapira,<sup>1</sup> Jotham Suez,<sup>1</sup> Anouk C. Tengeler,<sup>1</sup> Lior Abramson,<sup>1</sup> Meirav N. Katz,<sup>1,3</sup> Tal Korem,<sup>2</sup> Niv Zmora,<sup>3,4,5</sup> Yael Kuperman,<sup>6</sup> Inbal Biton,<sup>6</sup> Shlomit Gilad,<sup>7</sup> Alon Harmelin,<sup>6</sup> Hagit Shapiro,<sup>1</sup> Zamir Halpern,<sup>3,5</sup> Eran Segal,<sup>2</sup> and Eran Elinav<sup>1,\*</sup>



# ***Dysbiosis and chronic inflammatory diseases***

## **Depression**

*Mol Psychiatry*. 2016.  
doi: 10.1038/mp.2016.46

## **Atherosclerosis**

*J Am Heart Assoc*. 2015;4(11).

## **Obesity**

*Science*. 2013; 341; 6150

## **Cirrhosis**

*Nature*. 2014;513:59-64.

## **Rheumatoid arthritis**


*Nat Med*. 2015;21:895-905.

## **Type 2 diabetes**

*Nature*. 2015; 10;528:262-6

## **Cancer**

*Science*. 2015 27;350:1079-84.




# Is dysbiosis really to blame?

## Cultured gut microbiota from twins discordant for obesity modulate adiposity and metabolic phenotypes in mice


Vanessa K. Ridaura<sup>1</sup>, Jeremiah J. Faith<sup>1</sup>, Federico E. Rey<sup>1</sup>, Jiye Cheng<sup>1</sup>, Alexis E. Duncan<sup>2,3</sup>, Andrew L. Kau<sup>1</sup>, Nicholas W. Griffin<sup>1</sup>, Vincent Lombard<sup>4</sup>, Bernard Henrissat<sup>4,5</sup>, James R. Bain<sup>6,7,8</sup>, Michael J. Muehlbauer<sup>6</sup>, Olga Ilkayeva<sup>6</sup>, Clay F. Semenkovich<sup>9</sup>, Katsuhiko Funai<sup>9</sup>, David K. Hayashi<sup>10</sup>, Barbara J. Lyle<sup>11</sup>, Margaret C. Martini<sup>11</sup>, Luke K. Ursell<sup>12</sup>, Jose C. Clemente<sup>12</sup>, William Van Treuren<sup>12</sup>, William A. Walters<sup>13</sup>, Rob Knight<sup>12,14,15</sup>, Christopher B. Newgard<sup>6,7,8</sup>, Andrew C. Heath<sup>2</sup>, and Jeffrey I. Gordon<sup>1,\*</sup>

*Science*. 2013 September 6; 341(6150): . doi:10.1126/science.1241214.





# *Early life determinants of disease*



## **Antibiotic exposure <12 months associated with increased risk of**





- Allergy and asthma at 6 years of age
- Wheezing and eczema at 8 years of age
- Inflammatory bowel disease
- Obesity, central adiposity, and type 2 diabetes
- Type 1 diabetes
- Depression, anxiety, or psychosis

# Early life determinants of autoimmunity

## Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans

Tommi Vatanen,<sup>1,2,22</sup> Aleksandar D. Kostic,<sup>1,3,4,22</sup> Eva d'Hennezel,<sup>5,22</sup> Heli Silljander,<sup>6,7,8</sup> Eric A. Franzosa,<sup>1,4</sup> Moran Yassour,<sup>1</sup> Raivo Kolde,<sup>3</sup> Hera Vlamakis,<sup>1</sup> Timothy D. Arthur,<sup>1</sup> Anu-Maarit Hämäläinen,<sup>9</sup> Aleksandr Peet,<sup>10</sup> Vallo Tillmann,<sup>10</sup> Raivo Uibo,<sup>11</sup> Sergei Mokurov,<sup>12</sup> Natalya Dorshakova,<sup>13</sup> Jorma Ilonen,<sup>14,15</sup> Suvi M. Virtanen,<sup>16,17,18</sup> Susanne J. Szabo,<sup>5</sup> Jeffrey A. Porter,<sup>5</sup> Harri Lähdesmäki,<sup>2</sup> Curtis Huttenhower,<sup>1,4</sup> Dirk Gevers,<sup>1,23</sup> Thomas W. Cullen,<sup>5,23</sup> Mikael Knip,<sup>5,7,8,19,23</sup> on behalf of the DIABIMMUNE Study Group, and Ramnik J. Xavier<sup>1,3,20,21,23,\*</sup>

Cell 165, 842–853, May 5, 2016




# The prenatal influence of the microbiome

Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites



Alison N. Thorburn<sup>1</sup>, Craig I. McKenzie<sup>1</sup>, S.J. Shen<sup>1</sup>, Dragana Stanley<sup>2</sup>, Laurence Macia<sup>1</sup>, Linda J. Mason<sup>1</sup>, Laura K. Roberts<sup>1</sup>, Connie H.Y. Wong<sup>1</sup>, Raymond Shim<sup>1</sup>, Remy Robert<sup>1</sup>, Nina Chevalier<sup>1,3</sup>, Jian K. Tan<sup>1</sup>, Eliana Mariño<sup>1</sup>, Rob J. Moore<sup>4,5</sup>, Lee Wong<sup>6</sup>, Malcolm J. McConville<sup>7,8</sup>, Dedreia L. Tull<sup>8</sup>, Lisa G. Wood<sup>9</sup>, Vanessa E. Murphy<sup>9</sup>, Joerg Mattes<sup>9</sup>, Peter G. Gibson<sup>9</sup> & Charles R. Mackay<sup>1,10</sup>

NATURE COMMUNICATIONS | 6:7320 | DOI: 10.1038/ncomms8320



## Maternal fibre intake influences acetate levels



## Maternal acetate levels during pregnancy influence rates of allergic airways disease in offspring



# Microbiome and treatment outcomes





# Determinants of microbiome composition

## Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy


Ayelet Sivan,<sup>1\*</sup> Leticia Corrales,<sup>1\*</sup> Nathaniel Hubert,<sup>2</sup> Jason B. Williams,<sup>1</sup> Keston Aquino-Michaels,<sup>3</sup> Zachary M. Earley,<sup>2</sup> Franco W. Benyamin,<sup>1</sup> Yuk Man Lei,<sup>2</sup> Bana Jabri,<sup>2</sup> Maria-Luisa Alegre,<sup>2</sup> Eugene B. Chang,<sup>2</sup> Thomas F. Gajewski<sup>1,2†</sup>

SCIENCE 27 NOVEMBER 2015 • VOL 350 ISSUE 6264



### IMPRECISION MEDICINE

For every person they do help (blue), the ten highest-grossing drugs in the United States fail to improve the conditions of between 3 and 24 people (red).



Based on published number needed to treat (NNT) figures. For a full list of references, see Supplementary Information at [go.nature.com/4dr78L](http://go.nature.com/4dr78L).



# Using microbiome analysis to guide therapy

## THE PRECISION MEDICINE INITIATIVE



*“Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type — that was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as taking our temperature?”*  
- President Obama, January 30, 2015

## NATIONAL CANCER INSTITUTE PRECISION MEDICINE IN CANCER TREATMENT

Discovering unique therapies that treat an individual's cancer based on the specific genetic abnormalities of that person's tumor.



# A precision approach to respiratory medicine



Chocolate agar + Bacitracin  
35-37 C, 5-10% CO<sub>2</sub>, 40-48h



*Haemophilus influenzae*  
*Moraxella catarrhalis*  
*Streptococcus pneumoniae*  
*Staphylococcus aureus*

MacConkey agar  
35-37 C, air, 40-48h



*Pseudomonas aeruginosa*



Antibiotic  
susceptibility testing

## Disease course

### A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis

Geraint B. Rogers<sup>1</sup>, Nur Masirah M. Zain<sup>2</sup>, Kenneth D. Bruce<sup>2\*</sup>, Lucy D. Burr<sup>1</sup>, Alice C. Chen<sup>1</sup>, Damian W. Rivett<sup>3</sup>, Michael A. McGuckin<sup>1</sup>, and David J. Serisier<sup>1,4\*</sup>

<sup>1</sup>Immunity, Infection, and Inflammation Program, Mater Research Institute, University of Queensland, and Translational Research Institute, Woolloongabba, Queensland, Australia; <sup>2</sup>Institute of Pharmaceutical Science, King's College London, and <sup>3</sup>Division of Ecology and Evolution, Department of Life Sciences, Imperial College London, London, United Kingdom; and <sup>4</sup>Department of Respiratory Medicine, Mater Adult Hospital, South Brisbane, Australia

AnnalsATS Volume 11 Number 4 | May 2014

## Treatment efficacy

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Geraint B Rogers, Kenneth D Bruce, Megan L Martin, Lucy D Burr, David J Serisier

## Adverse outcomes

Inhaled Corticosteroids and the Risk of Pneumonia in People With Asthma

A Case-Control Study

Tricia McKeever, PhD; Timothy W. Harrison, MD; Richard Hubbard, MD; and Dominick Shaw, MD

CHEST 2013; 144(6):1788-1794

# ***Challenges and opportunities***

***How do we balance treatments for discrete conditions against their impact on other physiological systems?***

***Can we manage the human microbiome to influence patient health and therapeutic efficacy?***

***Thank you***

